Introduction: Balloon pulmonary valvuloplasty (BPV) has become the treatment of choice for the relief of moderate to severe pulmonary stenosis (PS).
Introduction
Pulmonary stenosis (PS) accounts for about 10-12% of congenital heart disease 1 . Since the first description of balloon pulmonary valvuloplasty (BPV) in 1982 by Kan, the procedure has been extensively utilized by several groups of workers for relief of PS 2 . BPV has now become the treatment of choice for the relief of moderate and severe valvular PS in all age groups and has completely replaced surgical valvotomy 3 . It effectively reduces right ventricle-pulmonary artery systolic pressure gradient 2 . It should be considered as the treatment of choice for children with PS based on its excellent outcome, lesser trauma and fewer _____________________________________________ 1 Department of Cardiology, Shahid Gangalal National Heart Centre, Bansbari, Kathmandu, Nepal (Received on 10 August 2013: Accepted after revision on 27 September 2013) complications 4, 5 . It is generally recommended that the procedure be performed for peak-to-peak gradient in excess of 50 mmHg 6 .
Objective
To evaluate the immediate results of BPV in children at Shahid Gangalal National Heart Centre (SGNHC), Kathmandu, Nepal
Method
This is a retrospective longitudinal cohort study of 70 consecutive patients who are less than 15 years old with moderate (≥50mmHg) and severe(≥70mmHg) PS who underwent BPV with Tyshak balloon catheter at SGNHC over a period of 7 years from June 2006 to June 2013. Six cases were excluded from this study. Three cases were excluded as PS was associated with other cardiac anomalies (PDA in 2, ASD in 1). Three others were excluded as there was no balloon dilatation (unsuitable balloon size in 1 and inability to cross the pulmonary valve with the wire in 2). This study was approved by the ethical review board of SGNHC. The gradient was measured before and immediately after valvuloplasty. Data were collected by reviewing medical records, noninvasive studies and cardiac catheterization laboratory.
Technique of BPV:
Vascular access was via femoral vein; right ventricular (RV) angiography was performed with a Berman balloon catheter in lateral view initially. Haemodynamic data, including RV pressure and pulmonary artery (PA) pressure were documented during catheterization with a Swan-Ganz catheter. Our technique of balloon dilatation of the pulmonary valve was similar to that described by Kan et al 2 ; a long J tipped exchange guide wire (260cm) was used to advance the balloon to the pulmonary valve site. Singleballoon technique was performed via femoral vein, with balloon size 15% greater than the pulmonary valve annulus diameter measured on 2D-Echo Doppler evaluation. Repeated balloon dilation 2-3times was performed and each inflation-deflation time was no more than 30 seconds. We define BPV a success if peak-topeak pressure gradient (PG) by pull back pressure tracing post BPV was ≤35mmHg immediately after the procedure. All patients were given heparin in a dose of 100 units per kg during the procedure. The patient usually stayed in hospital for one day after the procedure, received intravenous antibiotics and was discharged after performing 2D-Echo Doppler evaluation.
Statistical analysis: All data were expressed as mean ± SD or median with range. Paired t-test was used to compare the mean right ventricular pressure and pressure gradient across the pulmonary valve before and after the procedure. A P value less than 0.05, was considered significant.
Results
Altogether 70 patients (37 male and 33 female) were included in this study. The ages ranged from 14 days to 15 years with a mean age of 8.7±4.2years. Three (4.2%) cases had to undergo repeat procedure. Eight patients had moderate PS and 62 had severe PS. After BPV, there was a significant reduction in the right ventricular peak pressure (RVP), from 111.3±43.2 mmHg to 57.0±25.9 mmHg (p<0.001). Peak-to-peak pressure gradient across the pulmonary valve decreased from 76.5±25.1 mmHg to 32.0±20.9 mm-Hg (p<0.001). In 52 (74.2%) patients, peak-to-peak systolic pressure gradient across pulmonary valve decreased below 35 mmHg. In 11 (15.8%) patients it was above 35 mmHg but below 50 mmHg. In only 7 (10.0%) patients was it more than 50 mmHg. There were no major complications, such as severe pulmonary regurgitation or death. All the patients were discharged the day after the procedure.
The demographic and clinical profile of the patients is shown in Table 1 Comparison of pressures before and immediately after BPV is shown in Table 2 . Results based upon peak-to-peak pressure gradient across pulmonary valve are shown in Table 3 . 3, 8, 9 . Our study confirms the safety and effectiveness of BPV in children with PS.
The peak-to-peak pressure gradient across pulmonary valve decreased from 76.5±25.1mmHg to 32.0±20.9 mmHg after BPV which is comparable to studies from other countries 9, 10, 11 .
A good outcome, defined as a residual catheter gradient <36 mmHg, was achieved in 74.2% patients which is comparable to 77% in a similar study from Iran 12 . But when the residual pressure gradient (PG) after BPV <25 mmHg is considered successful as considered in Sri Lankan study 11 , our study showed 51.4% success rate which is slightly lower than their study (60%).
In our study, procedure failure was mainly due to an inability to cross the pulmonary valve and unsuitable balloon similar to Sri Lankan study 11 .
In general, after BPV, there is a decrease of RV pressure ranging from 39 to 71% and peak pressure gradient across pulmonary valve ranging from 45 to 93% 13 . In our study, there was a 50% decrease in RV pressure, and 62% reduction of peak pressure gradient across pulmonary valve after the procedure.
In our study there were no serious complications such as severe pulmonary regurgitation or annular laceration. Complications are common when balloon to annulus ratio exceeds 30% 14 . However, in our study we used a balloon size about 25% greater than the annulus diameter.
Conclusions
The immediate outcomes of balloon pulmonary valvuloplasty in children are excellent. BPV is a safe, effective and reliable treatment for patients with PS and is the treatment of choice in patients with symptomatic pulmonary stenosis.
